Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine Versus a 13-Valent Vaccine in Infants: A Systematic Review and Meta-Analysis
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The 20-valent pneumococcal conjugate vaccine (PCV20) showed lower immune responses for shared serotypes compared to the 13-valent vaccine (PCV13). However, PCV20 provides broader protection against additional serotypes linked to invasive pneumococcal disease (IPD).
Area Of Science
- Pediatric Infectious Diseases
- Vaccinology
- Immunology
Background
- The 20-valent pneumococcal conjugate vaccine (PCV20) offers expanded serotype coverage compared to the 13-valent vaccine (PCV13).
- PCV20 was approved for infants and children based on comparative safety and immunogenicity studies.
Purpose Of The Study
- To conduct a meta-analysis summarizing evidence on the comparative immunogenicity of PCV20 versus PCV13 in infants.
- To evaluate immune responses elicited by PCV20 and PCV13 across different serotypes and vaccination schedules.
Main Methods
- Systematic literature search of major databases (PubMed, Web of Science, Scopus, Cochrane, ClinicalTrials.gov) for randomized clinical trials.
- Inclusion of studies comparing PCV20 and PCV13 immunogenicity in infants (<2 years) with predefined outcomes.
- Random-effects meta-analysis using the Hartung-Knapp-Sidik-Jonkman method, assessing risk of bias with RoB 2.0 tool.
Main Results
- Four studies involving 4093 infants were included, comparing immunogenicity post-primary series and booster doses.
- PCV20 demonstrated lower immune responses for the 13 shared serotypes based on GMR and OPA, but no significant difference in the DP outcome.
- Higher, though not always statistically significant, immune responses were observed for the additional serotypes in PCV20.
Conclusions
- PCV20 elicits lower immune responses for serotypes shared with PCV13, but offers broader protection against seven additional serotypes associated with invasive pneumococcal disease (IPD).
- Further research is needed to strengthen the evidence base for PCV20.
- Ongoing surveillance of IPD is crucial for monitoring serotype prevalence and informing vaccine policy.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Overview
Vaccination is the administration of antigenic material from pathogens to confer immunity against a specific microorganism. Vaccination primes the immune system to recognize and mount an immune response faster and more effectively if the real pathogen is encountered. Vaccinations are one of the most efficient ways to protect both individual humans and the general public from disease. A growing anti-vaccination skepticism risks the successes of vaccination programs that helped reduce...
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Immunity, along with the ability to limit pathogen growth to prevent significant body tissue damage, can be gained either by (1) actively developing an immune response within the individual after exposure to a pathogen or after getting vaccinated or (2) passively transferring immune components from an immune individual to one who is nonimmune. Both these forms of immunity can be found naturally and in medical practices.
Active Immunity
Active immunity refers to the resistance one develops...
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...